中性粒細胞減少症市場：現況分析與預測（2023-2030）

Neutropenia Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年02月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計 2023 年至 2030 年中性粒細胞減少症市場的複合年增長率約為 5.5%。中性粒細胞減少症是一種以中性粒細胞數量減少為特徵的疾病，中性粒細胞是免疫系統必需的白血球類型。中性粒細胞減少症可由多種原因引起，包括化療、某些藥物和潛在的醫療狀況。中性粒細胞減少症市場包括旨在解決中性粒細胞減少症和改善患者預後的藥物介入、治療方法、診斷工具和支持性護理。癌症治療（尤其是化療）引起的中性粒細胞減少症盛行率不斷增加，正在推動市場發展。癌症患者經常會出現中性粒細胞減少症的副作用，這增加了對治療幹預措施的需求，以管理和預防相關併發症。例如，根據泛美衛生組織估計，2023年，全球將新增2,000萬癌症病例，1,000萬人因癌症死亡。未來 20 年，癌症負擔將增加約 60%，給衛生系統、人民和社區帶來進一步的壓力。

依類型劃分，市場分為先天性嗜中性白血球減少症、發燒性嗜中性白血球減少症、週期性嗜中性白血球減少症、自體免疫性嗜中性白血球減少症等。其中，發燒性嗜中性白血球減少症市場的複合年增長率較高，因為它與感染的脆弱性增加有關，特別是在接受化療等癌症治療的人群中，預計該市場將會成長。當癌症患者出現發燒且嗜中性球計數較低（中性粒細胞減少症）時，就會出現發燒性疾病，通常表示有潛在感染。發燒性嗜中性白血球減少症會帶來嚴重感染的重大風險，如果沒有快速有效地處理，可能會導致危及生命的併發症。

依治療方式，市場分為抗生素治療、集落刺激因子治療、粒細胞輸注等。其中，集落刺激因子治療領域預計將以較高的複合年增長率成長。集落刺激因子（CSF）治療領域在中性粒細胞減少症市場中非常重要，因為它在治療中性粒細胞減少症方面發揮關鍵作用。中性粒細胞減少症通常是癌症治療的副作用，腦脊髓液治療透過刺激嗜中性球（一種白血球）的產生來幫助降低感染風險。由於化療引起的中性粒細胞減少症的盛行率不斷增加以及對有效支持治療的需求，該領域正在經歷增長。

依最終使用者劃分，市場分為醫院、家庭護理、專科中心等。其中，醫院類別預計在預測期內中性粒細胞減少症招募量將增加。由於癌症發生率不斷上升以及廣大民眾對癌症的認識不斷提高，到醫院就診和治療的患者數量不斷增加。中性粒細胞減少症市場的醫院部分被認為是關鍵的成長因素。醫院在中性粒細胞減少症的診斷、治療和管理中發揮核心作用，特別是在需要密切監測、專門護理和乾預的嚴重病例中。此外，嚴重的中性粒細胞減少症，尤其是伴隨發燒的中性粒細胞減少症，可能需要住院治療。醫院提供住院服務，患者接受重症監護、持續監測以及出現併發症時的快速介入。

為了更了解中性粒細胞減少症產業的市場實施情況，我們根據其在北美、歐洲、亞太地區和世界其他地區的全球影響力對市場進行了分析。北美中性粒細胞減少症市場的推動因素包括癌症發病率上升、醫療保健專業人員和普通大眾對中性粒細胞減少症的認識不斷增強、先進成像技術的市場發展以及治療選擇數量的增加。預計該市場將在未來繼續增長。未來。例如，根據美國癌症協會的數據，2020 年，癌症是美國僅次於心臟病的第二大死因。預計 2022 年美國將有約 609,360 人死於癌症，相當於每天約 1,670 人死亡。

參與市場的主要公司包括輝瑞公司、諾華公司、阿斯特捷利康公司、梯瓦製藥工業有限公司、邁蘭公司、賽諾菲公司、葛蘭素史克公司、默克公司、西普拉公司、希根公司等。

The Neutropenia market is expected to register a CAGR of approx. 5.5% over the period of 2023-2030. The Neutropenia is a medical condition characterized by a low count of neutrophils; a type of white blood cell essential for the immune system. Neutropenia can result from various causes, including chemotherapy, certain medications, or underlying medical conditions. The market encompasses pharmaceutical interventions, therapeutic approaches, diagnostic tools, and supportive care aimed at addressing neutropenia and improving patient outcomes. The Growing prevalence of neutropenia induced by cancer treatments, particularly chemotherapy is boosting the neutropenia market. Cancer patients often experience neutropenia as a side effect, increasing the demand for therapeutic interventions to manage and prevent associated complications. For instance, according to PAHO, in 2023, Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.

Based on the type, the market has been categorized into congenital neutropenia, febrile neutropenia, cyclic neutropenia, autoimmune neutropenia and others. Among them, the febrile neutropenia segment is expected to grow at a higher CAGR in the market due to its association with increased vulnerability to infections, especially among individuals undergoing cancer treatments such as chemotherapy. Febrile neutropenia occurs when cancer patients with a low neutrophil count (neutropenia) develop a fever, which is often indicative of an underlying infection. Febrile neutropenia poses a significant risk of severe infections, and if not managed promptly and effectively, it can lead to life-threatening complications.

Based on the treatment, the market has been categorized into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, and others. Among them, the colony-stimulating factor therapy segment is expected to grow at a higher CAGR in the market. The colony-stimulating factor (CSF) therapy segment is crucial in the Neutropenia market because it plays a key role in managing neutropenia, particularly in cases where the condition is induced by chemotherapy or other medical treatments. Neutropenia is often a side effect of cancer treatments, and CSF therapy helps stimulate the production of neutrophils, a type of white blood cell, to reduce the risk of infections. This segment has witnessed growth due to the increasing prevalence of chemotherapy-induced neutropenia and the need for effective supportive care.

Based on the end-user, the market has been categorized into Hospitals, Homecare ,Speciality Centres, and Others. Among them, the hospital category is to witness higher adoption of Neutropenia during the forecast period. The rising incidence of cancer and the growing awareness of cancer among the general population has led to an increased number of patients seeking medical attention and Type at hospitals. The hospital segment in the Neutropenia market is considered a crucial and growing component. Hospitals play a central role in the diagnosis, treatment, and management of neutropenia, particularly in severe cases where close monitoring, specialized care, and interventions are necessary. Moreover, Severe neutropenia, especially cases involving febrile neutropenia, may require hospitalization. Hospitals offer inpatient services where patients can receive intensive care, continuous monitoring, and prompt intervention in case of complications.

For a better understanding of the market adoption of the Neutropenia industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America neutropenia market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of neutropenia among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.

Some of the major players operating in the market include Pfizer Inc., Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Mylan N.V, Sanofi , GSK plc , Merck & Co., Inc, Cipla Inc, Seagen, Inc.

1. MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Neutropenia Market
2.2.Research Methodology of the Neutropenia Market
2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE NEUTROPENIA MARKET

6. GLOBAL NEUTROPENIA MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY TYPE

7.1.Congenital Neutropenia
7.2.Febrile Neutropenia
7.3.Cyclic Neutropenia
7.4.Autoimmune Neutropenia
7.5.Others

8. MARKET INSIGHTS BY TREATMENT

8.1.Antibiotic Therapy
8.2.Colony-Stimulating Factor Therapy
8.3.Granulocyte Transfusion
8.4.Others

9. MARKET INSIGHTS BY END-USERS

9.1.Hospitals
9.2.Homecare
9.3.Speciality Centres
9.4.Others

10. MARKET INSIGHTS BY REGION

10.1NORTH AMERICA NEUTROPENIA MARKET
- 10.1.1.U.S.
- 10.1.2.Canada
- 10.1.3.Rest of North America
10.2EUROPE NEUTROPENIA MARKET
- 10.2.1.Germany
- 10.2.2.U.K.
- 10.2.3.France
- 10.2.4.Italy
- 10.2.5.Spain
- 10.2.6.Rest of Europe
10.3ASIA PACIFIC NEUTROPENIA MARKET
- 10.3.1.China
- 10.3.2.Japan
- 10.3.3.India
- 10.3.4.Rest of Asia-Pacific
10.4REST OF THE WORLD NEUTROPENIA MARKET